Cargando…

Clinical Efficacy of Ovarian Cancer Screening

Various trials of ovarian cancer screening programs have been reported worldwide. In 2011, one of the most famous papers indicated that annual screening using CA125/transvaginal sonography (TVS) did not reduce ovarian cancer mortality in the United States of America (USA). To investigate the validit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koshiyama, Masafumi, Matsumura, Noriomi, Konishi, Ikuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2016
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934039/ https://www.ncbi.nlm.nih.gov/pubmed/27390606 http://dx.doi.org/10.7150/jca.14615

Ejemplares similares

Subtypes of Ovarian Cancer and Ovarian Cancer Screening
por: Koshiyama, Masafumi, et al.
Publicado: (2017)

Recent Concepts of Ovarian Carcinogenesis: Type I and Type II
por: Koshiyama, Masafumi, et al.
Publicado: (2014)

Epigenetic and genetic dispositions of ovarian carcinomas
por: Yamaguchi, Ken, et al.
Publicado: (2014)

Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer
por: Yamanoi, Koji, et al.
Publicado: (2016)

Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients
por: Horikawa, Naoki, et al.
Publicado: (2015)

Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment
por: Horikawa, Naoki, et al.
Publicado: (2020)

Clinical approaches to treating papillary squamous cell carcinoma of the uterine cervix
por: Nagura, Michikazu, et al.
Publicado: (2014)

The effect of the type of dietary protein on the development of ovarian cancer
por: Taha, Ahmed A.A., et al.
Publicado: (2018)

Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer
por: Abou-Taleb, Hisham A, et al.
Publicado: (2016)

Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy
por: Koshiyama, Masafumi, et al.
Publicado: (2017)

Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer
por: Sakae, Chieko, et al.
Publicado: (2016)

Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma
por: Abou-Taleb, Hisham, et al.
Publicado: (2016)

ASGO 2nd International Workshop on Gynecologic Oncology
por: Matsumura, Noriomi, et al.
Publicado: (2013)

Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction
por: Mandai, Masaki, et al.
Publicado: (2015)

Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics
por: Konishi, Ikuo, et al.
Publicado: (2022)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Histotype-specific copy-number alterations in ovarian cancer
por: Huang, Ruby YunJu, et al.
Publicado: (2012)

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Acquisition of a side population fraction augments malignant phenotype in ovarian cancer
por: Yamanoi, Koji, et al.
Publicado: (2019)

Further Possible Mechanisms of Dipeptidyl Peptidase-4 Inhibitors to Decrease Blood Glucose in Subjects with Type 2 Diabetes
por: Koshiyama, Hiroyuki
Publicado: (2011)

Explanation of the Insulin Paradox From the Evolutionary Point of View
por: Koshiyama, Hiroyuki
Publicado: (2012)

Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
por: Murakami, Ryusuke, et al.
Publicado: (2021)

Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival
por: Amano, Yasuaki, et al.
Publicado: (2015)

Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs
por: Nakai, Hidekatsu, et al.
Publicado: (2022)

Scientific evaluation of alleged findings in HPV vaccines: Molecular mimicry and mouse models of vaccine‐induced disease
por: Matsumura, Noriomi, et al.
Publicado: (2022)

Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy
por: Murakami, Kosuke, et al.
Publicado: (2020)

Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation
por: Taki, Mana, et al.
Publicado: (2018)

Recurrence of a carcinoid tumor of the ovary 13 years after the primary surgery: A case report
por: AMANO, YASUAKI, et al.
Publicado: (2013)

Adult granulosa cell tumors of the ovary: a retrospective study of 30 cases with respect to the expression of steroid synthesis enzymes
por: Kitamura, Sachiko, et al.
Publicado: (2017)

Critical evaluation on roles of macrophagic myofasciitis and aluminum adjuvants in HPV vaccine–induced adverse events
por: Matsumura, Noriomi, et al.
Publicado: (2023)

Ovarian Cancer: A Clinical Challenge That Needs Some Basic Answers
por: Lawrenson, Kate, et al.
Publicado: (2009)

Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
por: Ohsuga, Takuma, et al.
Publicado: (2017)

Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer
por: Takamatsu, Shiro, et al.
Publicado: (2023)

Molecular Histopathology for Establishing Diagnostic Method and Clinical Therapy for Ovarian Carcinoma
por: Hayashi, Takuma, et al.
Publicado: (2023)

Perspectives on Ovarian Cancer 1809 to 2022 and Beyond
por: Lawton, Frank G., et al.
Publicado: (2022)

The Effects of the Dietary and Nutrient Intake on Gynecologic Cancers
por: Koshiyama, Masafumi
Publicado: (2019)

Screening for prostate cancer: are organized screening programs necessary?
por: Roobol, Monique J.
Publicado: (2018)

Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective
por: Rose, Peter G.
Publicado: (2022)

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
por: Takaya, Hisamitsu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2739m3rnkhejkauoiim3ija7go